In a retrospective study tracking patients diagnosed with both multiple sclerosis and uveitis, ocular inflammation flare-ups occurred largely independently of neurological relapses. Researchers evaluating 49 adult patients found that episodes of uveitis and neurological attacks were temporally dissociated in 94.2 percent of documented cases, highlighting a distinct clinical pattern between central nervous system events and intraocular inflammatory activity.
The temporal relationship between uveitis and neurological relapses in multiple sclerosis–associated uveitis is poorly documented. Furthermore, clinicians have sought clearer evidence regarding whether systemic disease-modifying therapies targeted at multiple sclerosis exert a measurable influence on the long-term course and recurrence of inflammatory eye disease.
To investigate these questions, investigators conducted a retrospective multicenter study drawing patient records from the Lyon Uvéite cohort, the European Database for Multiple Sclerosis, and broader open calls for case reporting. Eligible individuals were at least 18 years of age, held a confirmed multiple sclerosis diagnosis meeting McDonald criteria, and had their uveitis independently validated by an ophthalmologist.
The study protocol defined concomitant disease activity as uveitis and neurological flares taking place within a three-month window. Across the cohort, the 49 included patients were followed for a median duration of 19 years, with an interquartile range spanning 10 to 25 years, providing extensive longitudinal documentation of disease trajectories and therapeutic interventions over time.
To evaluate treatment effectiveness, the authors analyzed the probability of uveitis recurrence by comparing multiple sclerosis-targeted disease-modifying therapies directly against standard uveitis-directed treatments. Recurrent-event analyses accounting for time-varying treatment exposure revealed that patients receiving multiple sclerosis-targeted therapies experienced a significantly lower risk of uveitis relapse, yielding an adjusted hazard ratio of 0.20 with a 95 percent confidence interval of 0.08 to 0.54 and a p-value of 0.002.
The authors concluded that uveitis in individuals with multiple sclerosis operates largely dissociated from active neurological relapses, while systemic disease-modifying therapies directed at multiple sclerosis are associated with reduced uveitis recurrences. However, the authors noted that these exploratory findings require confirmation in prospective studies.
Subject of Research: Clinical course of multiple sclerosis-associated uveitis and treatment outcomes
Article Title: Clinical course of multiple sclerosis-associated uveitis: a retrospective series of 49 cases
Article References: Gil, W., Mainbourg, S., Jacquot, R., Trefond, L., Olagne, L., Clavelou, P., Trouillier, S., Bardy, A., Andre, M., Androdias-Condemine, G., Vasseneix, C., Kodjikian, L., El-Jammal, T., Vukusic, S., & Sève, P. (2026). Clinical course of multiple sclerosis-associated uveitis: a retrospective series of 49 cases. Journal of Ophthalmic Inflammation and Infection. https://doi.org/10.1186/s12348-026-00624-8
Image Credits: AI Generated
DOI: 10.1186/s12348-026-00624-8
Keywords: multiple sclerosis, uveitis, neuro-ophthalmology, disease-modifying therapies, ocular inflammation, neurological relapses, ophthalmology, retrospective study, McDonald criteria, Kaplan-Meier analysis, EDMUS, Lyon Uvéite cohort, autoimmune disease, clinical neurology, ocular flare, recurrent-event analysis
News Source: Ophelia Keating. (November 19, 2026). Multiple Sclerosis Treatments Associated with Reduced Uveitis Relapses in Retrospective Study. Scienmag.



